小柯机器人

科学家开发出检测SARS-CoV-2中和抗体的新方法
2020-07-26 20:25

新加坡国立大学Lin-Fa Wang、Danielle E. Anderson等研究人员,合作开发出一种基于抗体介导的ACE2-突刺蛋白相互作用阻断的SARS-CoV-2病毒中和测试方法。相关论文于2020年7月23日在线发表于《自然—生物技术》。

研究人员报道了一种SARS-CoV-2替代病毒中和测试,该测试以同种型和物种无关的方式检测靶向病毒刺突(S)蛋白受体结合域的总免疫主导中和抗体。这一简单而快速的测试是基于抗体介导的血管紧张素转化酶2(ACE2)受体蛋白与受体结合域之间相互作用的阻断。
 
该测试已在两个不同国家的两个队列中进行了验证,该测试达到了99.93%的特异性和95-100%的敏感性,并区分了对几种人类冠状病毒的抗体反应。这一替代病毒中和测试不需要生物安全级别3的实验室,因此对于研究和临床应用而言,能够广泛地使用。
 
据了解,目前迫切需要一种强有力的血清学检测方法来检测抗SARS-CoV-2的中和抗体,不仅要确定感染率、群体免疫和预期的体液保护,还要确定临床试验期间和大规模疫苗接种后的疫苗效力。当前的金标准是需要活病原体和3级生物安全实验室的常规病毒中和测试。
 
附:英文原文

Title: A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction

Author: Chee Wah Tan, Wan Ni Chia, Xijian Qin, Pei Liu, Mark I.-C. Chen, Charles Tiu, Zhiliang Hu, Vivian Chih-Wei Chen, Barnaby E. Young, Wan Rong Sia, Yee-Joo Tan, Randy Foo, Yongxiang Yi, David C. Lye, Danielle E. Anderson, Lin-Fa Wang

Issue&Volume: 2020-07-23

Abstract: A robust serological test to detect neutralizing antibodies to SARS-CoV-2 is urgently needed to determine not only the infection rate, herd immunity and predicted humoral protection, but also vaccine efficacy during clinical trials and after large-scale vaccination. The current gold standard is the conventional virus neutralization test requiring live pathogen and a biosafety level 3 laboratory. Here, we report a SARS-CoV-2 surrogate virus neutralization test that detects total immunodominant neutralizing antibodies targeting the viral spike (S) protein receptor-binding domain in an isotype- and species-independent manner. Our simple and rapid test is based on antibody-mediated blockage of the interaction between the angiotensin-converting enzyme 2 (ACE2) receptor protein and the receptor-binding domain. The test, which has been validated with two cohorts of patients with COVID-19 in two different countries, achieves 99.93% specificity and 95–100% sensitivity, and differentiates antibody responses to several human coronaviruses. The surrogate virus neutralization test does not require biosafety level 3 containment, making it broadly accessible to the wider community for both research and clinical applications.

DOI: 10.1038/s41587-020-0631-z

Source: https://www.nature.com/articles/s41587-020-0631-z

Nature Biotechnology:《自然—生物技术》,创刊于1996年。隶属于施普林格·自然出版集团,最新IF:68.164
官方网址:https://www.nature.com/nbt/
投稿链接:https://mts-nbt.nature.com/cgi-bin/main.plex


本期文章:《自然—生物技术》:Online/在线发表

分享到:

0